Brief: SOBI Enters Strategic Partnership With Innate Pharma To License Lacutamab In T-Cell Lymphoma
10/08/2026 07:38
BRIEF-SOBI Enters Strategic Partnership With Innate Pharma To License Lacutamab In T-Cell Lymphoma Aug 10 (Reuters) - Swedish Orphan Biovitrum AB (publ) SOBIV.ST:
SOBI ENTERS STRATEGIC PARTNERSHIP WITH INNATE PHARMA TO LICENSE LACUTAMAB IN T-CELL LYMPHOMA
SWEDISH ORPHAN BIOVITRUM - SOBI TO PAY INNATE PHARMA $75 MILLION ON CLOSING
SWEDISH ORPHAN BIOVITRUM - INNATE ELIGIBLE FOR UP TO $40 MILLION IN NEAR-TERM DEVELOPMENT MILESTONES CONNECTED TO SEZARY SYNDROME
SWEDISH ORPHAN BIOVITRUM - INNATE ELIGIBLE FOR UP TO $465 MILLION IN FUTURE MILESTONES
SWEDISH ORPHAN BIOVITRUM - INNATE TO RECEIVE TIERED DOUBLE-DIGIT ROYALTIES ON NET SALES
Source text: ID:nPn17QFNga
Further company coverage: SOBIV.ST
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Swedish Orphan Biovitrum AB (publ)
See all newsTop of the Street: SOBI, Sonova, BAT, Imperial Brands
SOBI slips after Ionis lowers Tryngolza sales forecast
Brief: Swedish Orphan Biovitrum Executive Sells, Buys Shares
Europe Research Roundup: Centrica, Fuchs, URW
Brief: Swedish Orphan Biovitrum Proposes Börje Ekholm As New Chair And Board Member At 2027 AGM